_256_384.jpg)
News | December 08, 2021
IPM registers 6 % yoy revenue growth in Nov 2021.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The start-up has announced the scheme to mark World Diabetes Day
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Acute therapies continue to report strong growth compared to chronic ones.
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Subscribe To Our Newsletter & Stay Updated
